StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Spyre Therapeutics's pe ratio was 0.8× on Jan 31, 2024.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 20240.8×+0.1
2023Dec 29, 20230.7×–

More Spyre Therapeutics figures

See a number that looks wrong?